Chunhui Huang, Shane Gao, Xiao Zheng, Xichen Song, Jiaxi Wu, Kai Liao, Jiawei Li, Yingqi Lin, Caijuan Li, Yaqun Lu, Jiahao Feng, Huiyi Wei, Lu Wang, Hao Xu, Wei Wang, Yizhi Chen, Jianhao Wu, Jiale Gao, Junzhu Song, Chunxiang Shi, Jun Zhang, Sen Yan
Parkinson's disease (PD) is a neurodegenerative disease caused by the loss of dopaminergic neurons (DNs). Currently, there is no treatment that can cure PD. Deep brain stimulation has been used to treat PD due to its good effectiveness, but there are safety issues. Therefore, noninvasive electrical stimulation (NES) may be an effective and safe strategy for the treatment of PD. Here, we performed NES treatment and NES combined with human adipose-derived stem cells-induced DN transplantation (NES-DN) on the PD monkey model to explore the therapeutic effect of NES on PD. The results show that NES or NES-DN can increase dopamine levels, improve mitochondrial dysfunction, reduce neuroinflammation, enhance synaptic function, and protect TH neurons, thereby improving the movement disorders of PD. Moreover, NES/NES-DN may exert immunomodulatory effects by regulating serpin family A member 3 in PD monkeys. Our results support the scientific basis and preclinical evidence for NES in the treatment of PD. Not only does NES alone improve PD, but NES combined with stem cell therapy can greatly enhance the therapeutic effect of PD.
{"title":"Therapeutic Effects of Noninvasive Electrical Stimulation in Combination Transplantation of Human Adipose-Derived Stem Cells-Derived Dopaminergic Neuron on the Monkey Model of Parkinson's Disease","authors":"Chunhui Huang, Shane Gao, Xiao Zheng, Xichen Song, Jiaxi Wu, Kai Liao, Jiawei Li, Yingqi Lin, Caijuan Li, Yaqun Lu, Jiahao Feng, Huiyi Wei, Lu Wang, Hao Xu, Wei Wang, Yizhi Chen, Jianhao Wu, Jiale Gao, Junzhu Song, Chunxiang Shi, Jun Zhang, Sen Yan","doi":"10.1002/mco2.70595","DOIUrl":"10.1002/mco2.70595","url":null,"abstract":"<p>Parkinson's disease (PD) is a neurodegenerative disease caused by the loss of dopaminergic neurons (DNs). Currently, there is no treatment that can cure PD. Deep brain stimulation has been used to treat PD due to its good effectiveness, but there are safety issues. Therefore, noninvasive electrical stimulation (NES) may be an effective and safe strategy for the treatment of PD. Here, we performed NES treatment and NES combined with human adipose-derived stem cells-induced DN transplantation (NES-DN) on the PD monkey model to explore the therapeutic effect of NES on PD. The results show that NES or NES-DN can increase dopamine levels, improve mitochondrial dysfunction, reduce neuroinflammation, enhance synaptic function, and protect TH neurons, thereby improving the movement disorders of PD. Moreover, NES/NES-DN may exert immunomodulatory effects by regulating serpin family A member 3 in PD monkeys. Our results support the scientific basis and preclinical evidence for NES in the treatment of PD. Not only does NES alone improve PD, but NES combined with stem cell therapy can greatly enhance the therapeutic effect of PD.</p>","PeriodicalId":94133,"journal":{"name":"MedComm","volume":"7 2","pages":""},"PeriodicalIF":10.7,"publicationDate":"2026-01-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12848770/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146088696","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Lei Jin, Bo Chen, Junbo Liao, Wenlong Guo, Zhiyuan Zhu, Salida Ali, Gilberto Ka-Kit Leung, Peng Wang, Karrie M. Kiang
Vacuole membrane Protein 1 (VMP1) is widely known to be an important mediator in the formation of autophagosomes, playing a crucial role in macroautophagic processes. Emerging evidence suggests that VMP1 may have context-dependent functions across diverse cancer types and different tumor microenvironments, both within the context of autophagy and beyond. Here, using glioblastoma as a cancer model, we found that VMP1 can promote tumor growth independent of its autophagic functions. We observed significant upregulation of VMP1 in glioblastoma, which was correlated with poorer prognosis, and its ability to promote tumor growth without altering autophagic flux. Bulk, single-cell, and spatial transcriptomics analyses revealed that the pro-angiogenic markers were enriched in glioblastomas with high VMP1 expression. We further validated that overexpression of VMP1 would enhance angiogenesis through VEGFA-VEGFR2 signaling-mediated activation in endothelial cells. Treatment with bevacizumab, a monoclonal antibody against VEGFA, significantly inhibited VMP1-driven tumor growth and prolonged survival in mice. Our study thus uncovered non-autophagic functions of VMP1 as an important mediator in glioblastoma angiogenesis with the potential for therapeutic targeting.
{"title":"Integrative Single-Cell Analysis Reveals Targetable Vacuole Membrane Protein 1-Mediated Mechanism of Tumor Angiogenesis in Glioblastoma","authors":"Lei Jin, Bo Chen, Junbo Liao, Wenlong Guo, Zhiyuan Zhu, Salida Ali, Gilberto Ka-Kit Leung, Peng Wang, Karrie M. Kiang","doi":"10.1002/mco2.70619","DOIUrl":"10.1002/mco2.70619","url":null,"abstract":"<p>Vacuole membrane Protein 1 (VMP1) is widely known to be an important mediator in the formation of autophagosomes, playing a crucial role in macroautophagic processes. Emerging evidence suggests that VMP1 may have context-dependent functions across diverse cancer types and different tumor microenvironments, both within the context of autophagy and beyond. Here, using glioblastoma as a cancer model, we found that VMP1 can promote tumor growth independent of its autophagic functions. We observed significant upregulation of VMP1 in glioblastoma, which was correlated with poorer prognosis, and its ability to promote tumor growth without altering autophagic flux. Bulk, single-cell, and spatial transcriptomics analyses revealed that the pro-angiogenic markers were enriched in glioblastomas with high VMP1 expression. We further validated that overexpression of VMP1 would enhance angiogenesis through VEGFA-VEGFR2 signaling-mediated activation in endothelial cells. Treatment with bevacizumab, a monoclonal antibody against VEGFA, significantly inhibited VMP1-driven tumor growth and prolonged survival in mice. Our study thus uncovered non-autophagic functions of VMP1 as an important mediator in glioblastoma angiogenesis with the potential for therapeutic targeting.</p>","PeriodicalId":94133,"journal":{"name":"MedComm","volume":"7 2","pages":""},"PeriodicalIF":10.7,"publicationDate":"2026-01-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12832072/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146055623","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Research on bedtime procrastination and depression has primarily used traditional psychometric approaches, limiting the ability to capture symptom-level temporal dynamics. This study aimed to examine within- and between-person associations between symptoms of depression and bedtime procrastination, considering sex differences. Data from 3296 adolescents followed over 18 months were used to explore symptom associations and their centrality in cross-sectional networks, as well as cross-lagged effects to clarify temporal relationships. In the within-person temporal network, not going to bed on time and trouble concentrating were the most influential symptoms for males and females, respectively. In the contemporaneous network, feeling worried and not going to bed on time were most central for males, while feeling tired and feeling worried were central for females. No significant sex differences were found in overall network strength (S = 0.10, p = 0.75) or structure (M = 0.48, p = 0.09). Positive associations were consistent at the between-person level. Overall, this study characterizes the symptom-to-symptom associations between depression and bedtime procrastination at both the within- and between-person levels, with notable sex differences. For males, sleep difficulties and worries were key factors, while for females, concentration issues and fatigue played a more significant role.
睡前拖延症和抑郁症的研究主要使用传统的心理测量方法,限制了捕捉症状水平时间动态的能力。这项研究的目的是在考虑到性别差异的情况下,研究抑郁症状和睡前拖延症之间的人际关系。来自3296名青少年超过18个月的数据被用来探索症状关联及其在横断面网络中的中心性,以及交叉滞后效应来澄清时间关系。在人际时间网络中,不按时睡觉和注意力不集中分别是对男性和女性影响最大的症状。在同时期的网络中,男性最主要的感觉是担心和不按时睡觉,而女性最主要的感觉是疲倦和担心。在整体网络强度(S = 0.10, p = 0.75)或结构(M = 0.48, p = 0.09)方面没有发现显著的性别差异。积极的联系在人际层面上是一致的。总的来说,这项研究在人体内和人与人之间的水平上描述了抑郁症和就寝拖延症之间的症状对症状的关联,并存在显著的性别差异。对于男性来说,睡眠困难和焦虑是关键因素,而对于女性来说,注意力不集中和疲劳是更重要的因素。
{"title":"Temporal Network Analysis of Bedtime Procrastination and Depression Among Adolescents: A Prospective Longitudinal Study","authors":"Tingting Gao, Wei Zhang, Yingying Su","doi":"10.1002/mco2.70620","DOIUrl":"10.1002/mco2.70620","url":null,"abstract":"<p>Research on bedtime procrastination and depression has primarily used traditional psychometric approaches, limiting the ability to capture symptom-level temporal dynamics. This study aimed to examine within- and between-person associations between symptoms of depression and bedtime procrastination, considering sex differences. Data from 3296 adolescents followed over 18 months were used to explore symptom associations and their centrality in cross-sectional networks, as well as cross-lagged effects to clarify temporal relationships. In the within-person temporal network, <i>not going to bed on time</i> and <i>trouble concentrating</i> were the most influential symptoms for males and females, respectively. In the contemporaneous network, <i>feeling worried</i> and <i>not going to bed on time</i> were most central for males, while <i>feeling tired</i> and <i>feeling worried</i> were central for females. No significant sex differences were found in overall network strength (<i>S</i> = 0.10, <i>p</i> = 0.75) or structure (<i>M</i> = 0.48, <i>p</i> = 0.09). Positive associations were consistent at the between-person level. Overall, this study characterizes the symptom-to-symptom associations between depression and bedtime procrastination at both the within- and between-person levels, with notable sex differences. For males, sleep difficulties and worries were key factors, while for females, concentration issues and fatigue played a more significant role.</p>","PeriodicalId":94133,"journal":{"name":"MedComm","volume":"7 2","pages":""},"PeriodicalIF":10.7,"publicationDate":"2026-01-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12832071/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146055638","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Mycoplasma pneumoniae infections resurged globally in 2023–2024 following a significant decline during the coronavirus disease 2019 (COVID-19) pandemic. To understand the genomic epidemiology of this resurgence in China, a nationwide 1-year genomic surveillance identified 9907 patients infected with M. pneumoniae, resulting in an overall positive rate of 10.05%. We developed a hybrid capture-based targeted next-generation sequencing (hc-tNGS) assay, obtaining 271 high-quality genomes directly from clinical samples. Phylogenetic analysis of a global collection of 562 M. pneumoniae genomes identified six distinct lineages, including three newly emerged main Chinese clades (MCCs) that co-circulated across various regions of China. Among these MCCs, one clade, comprising P1-1, ST17, and L4, was localized in Taiwan, while two others—P1-1, ST3, and L6 clade, and P1-2, ST14 and L2 clade—co-circulated in different regions of China during the 2023–2024 epidemic season. Notably, 96.31% of the isolates identified in this study exhibited a point mutation, primarily A2063G (95.94%). This study offers a comprehensive genomic characterization of the post-pandemic M. pneumoniae resurgence in China, highlighting the emergence and spread of resistant clades. These findings emphasize the importance of adopting a One Health approach to address the potential global public health threats posed by this resurgent pathogen.
{"title":"Genomic-Based Epidemiological Analysis of the Post-Pandemic Mycoplasma pneumoniae Resurgence","authors":"Hongbo Liu, Xiaoyi Zheng, Xinying Du, Yule Wang, Ying Xiang, Qi Wang, Sai Tian, Yufan Xian, Wenbin Chen, Hongbo Liu, Hui Wang, Chao Wang, Mingjuan Yang, Huiqun Jia, Xiaoying Li, Yunjie Dan, Libo Tong, Guohong Deng, Huiling Li, Fusheng Wang, Hongbin Song, Shaofu Qiu","doi":"10.1002/mco2.70617","DOIUrl":"10.1002/mco2.70617","url":null,"abstract":"<p><i>Mycoplasma pneumoniae</i> infections resurged globally in 2023–2024 following a significant decline during the coronavirus disease 2019 (COVID-19) pandemic. To understand the genomic epidemiology of this resurgence in China, a nationwide 1-year genomic surveillance identified 9907 patients infected with <i>M. pneumoniae</i>, resulting in an overall positive rate of 10.05%. We developed a hybrid capture-based targeted next-generation sequencing (hc-tNGS) assay, obtaining 271 high-quality genomes directly from clinical samples. Phylogenetic analysis of a global collection of 562 <i>M. pneumoniae</i> genomes identified six distinct lineages, including three newly emerged main Chinese clades (MCCs) that co-circulated across various regions of China. Among these MCCs, one clade, comprising P1-1, ST17, and L4, was localized in Taiwan, while two others—P1-1, ST3, and L6 clade, and P1-2, ST14 and L2 clade—co-circulated in different regions of China during the 2023–2024 epidemic season. Notably, 96.31% of the isolates identified in this study exhibited a point mutation, primarily A2063G (95.94%). This study offers a comprehensive genomic characterization of the post-pandemic <i>M. pneumoniae</i> resurgence in China, highlighting the emergence and spread of resistant clades. These findings emphasize the importance of adopting a One Health approach to address the potential global public health threats posed by this resurgent pathogen.</p>","PeriodicalId":94133,"journal":{"name":"MedComm","volume":"7 2","pages":""},"PeriodicalIF":10.7,"publicationDate":"2026-01-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12828172/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146055577","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Xinyu Zhang, Qingpei Lai, Jin Cao, Jerry Chi Fung Ching, Xinzhi Teng, Jiang Zhang, Shara Wee Yee Lee, Ge Ren, Jing Cai
Radiogenomics is a rapidly developing field that links radiological image features (radiomics) to genomic-level data (genomics, transcriptomics, and epigenomics), addressing the limitations of single-omic approaches. Radiomics provides a noninvasive and cost-effective method to capture tissue-level characteristics, while genomics elucidates the underlying molecular mechanisms. The central hypothesis is that the formation of imaging phenotypes is associated with the genetic and molecular processes, and thus can reflect underlying biological activities. This review presents the fundamental principles of radiogenomic analysis, covering key concepts in image analysis and gene analysis, as well as advanced analytical techniques for linking imaging and genomic data. Moreover, we summarize recent research findings across various human diseases, including oncology and nononcology, to highlight the current understandings and achievements in this field. Radiogenomics shows potential in clinical applications for elucidating disease mechanisms, detecting genomic variations noninvasively, and improving prognosis predictions. However, its implementation in clinical practice is limited by data scarcity, analytical methods, and barriers in translational processes. Future research should focus on enhancing data quality and establishing guidelines, developing analytical platforms, and validating current findings through animal models and clinical trials.
{"title":"Radiogenomics: Current Understandings and Future Perspectives","authors":"Xinyu Zhang, Qingpei Lai, Jin Cao, Jerry Chi Fung Ching, Xinzhi Teng, Jiang Zhang, Shara Wee Yee Lee, Ge Ren, Jing Cai","doi":"10.1002/mco2.70583","DOIUrl":"10.1002/mco2.70583","url":null,"abstract":"<p>Radiogenomics is a rapidly developing field that links radiological image features (radiomics) to genomic-level data (genomics, transcriptomics, and epigenomics), addressing the limitations of single-omic approaches. Radiomics provides a noninvasive and cost-effective method to capture tissue-level characteristics, while genomics elucidates the underlying molecular mechanisms. The central hypothesis is that the formation of imaging phenotypes is associated with the genetic and molecular processes, and thus can reflect underlying biological activities. This review presents the fundamental principles of radiogenomic analysis, covering key concepts in image analysis and gene analysis, as well as advanced analytical techniques for linking imaging and genomic data. Moreover, we summarize recent research findings across various human diseases, including oncology and nononcology, to highlight the current understandings and achievements in this field. Radiogenomics shows potential in clinical applications for elucidating disease mechanisms, detecting genomic variations noninvasively, and improving prognosis predictions. However, its implementation in clinical practice is limited by data scarcity, analytical methods, and barriers in translational processes. Future research should focus on enhancing data quality and establishing guidelines, developing analytical platforms, and validating current findings through animal models and clinical trials.</p>","PeriodicalId":94133,"journal":{"name":"MedComm","volume":"7 2","pages":""},"PeriodicalIF":10.7,"publicationDate":"2026-01-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12828074/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146055646","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
The 2022 global mpox outbreak caused by the monkeypox virus (MPXV) has underscored the urgent need for improved vaccine development. To address this need, we developed four candidate vaccine antigens based on conserved sequences of the MPXV A35R and M1R proteins utilizing a lipid nanoparticle (LNP) delivery system. All four vaccine candidates elicited varying degrees of humoral and cellular immune responses and conferred differential protection against MPXV and vaccinia virus (VACV) in BALB/c mice; notably, the dual-antigen vaccines MV1 and MV2 induced more potent immunogenicity, including higher neutralizing antibody titers and cytokine secretion levels. However, among the four candidates, only the dual-antigen vaccines MV1 and MV2 conferred protective efficacy in AGB6 mice and reduced infection-induced pox lesion formation, indicating that antigens containing both intracellular mature virus (IMV) and extracellular enveloped virus (EEV) targets may be key to exerting robust protection. Notably, MV2—which was designed via structural truncation and recombination based on poxvirus-broad-spectrum antibodies using the AlphaFold3 prediction platform and adopts a single-chain “dimer-like” configuration—exhibited not only optimal protective efficacy but also sustained durable immune responses and protection. These findings indicate that MV2 induces favorable immunogenicity and has potential for preventing MPXV and VACV infections, supporting its promise as a clinical vaccine candidate for MPXV.
{"title":"An mRNA Vaccine Based on Antigens From Conserved Regions of Monkeypox Virus A35R and M1R With a Dimer-Like Conformation Confers Protection Against Both Monkeypox Virus and Vaccinia Virus Infections in Mice","authors":"Cong Tang, Longhai Yuan, Yun Xie, Yun Yang, Yanan Zhou, Junbing Wang, Hao Yang, Rui Peng, Jiali Xu, Wenhai Yu, Qing Huang, Wenqi Quan, Baisheng Li, Youchun Wang, Shuaiyao Lu","doi":"10.1002/mco2.70614","DOIUrl":"10.1002/mco2.70614","url":null,"abstract":"<p>The 2022 global mpox outbreak caused by the monkeypox virus (MPXV) has underscored the urgent need for improved vaccine development. To address this need, we developed four candidate vaccine antigens based on conserved sequences of the MPXV A35R and M1R proteins utilizing a lipid nanoparticle (LNP) delivery system. All four vaccine candidates elicited varying degrees of humoral and cellular immune responses and conferred differential protection against MPXV and vaccinia virus (VACV) in BALB/c mice; notably, the dual-antigen vaccines MV1 and MV2 induced more potent immunogenicity, including higher neutralizing antibody titers and cytokine secretion levels. However, among the four candidates, only the dual-antigen vaccines MV1 and MV2 conferred protective efficacy in AGB6 mice and reduced infection-induced pox lesion formation, indicating that antigens containing both intracellular mature virus (IMV) and extracellular enveloped virus (EEV) targets may be key to exerting robust protection. Notably, MV2—which was designed via structural truncation and recombination based on poxvirus-broad-spectrum antibodies using the AlphaFold3 prediction platform and adopts a single-chain “dimer-like” configuration—exhibited not only optimal protective efficacy but also sustained durable immune responses and protection. These findings indicate that MV2 induces favorable immunogenicity and has potential for preventing MPXV and VACV infections, supporting its promise as a clinical vaccine candidate for MPXV.</p>","PeriodicalId":94133,"journal":{"name":"MedComm","volume":"7 2","pages":""},"PeriodicalIF":10.7,"publicationDate":"2026-01-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12828169/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146055594","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
The advent of neuroimmunology has dismantled the traditional doctrine of the brain's immune privilege, uncovering a sophisticated and dynamic bidirectional regulatory interplay between the nervous and immune systems. This review synthesizes pivotal advances in neuroimmunology, integrating recent anatomical and molecular discoveries to refine the understanding of neuro-immune communication. It highlights the pathological roles of neurotransmitters, cytokines, and their signaling networks in neurodegenerative, psychiatric, and neoplastic diseases, while critically examining contested regulatory mechanisms. The review further evaluates the clinical translational potential and challenges of innovative strategies such as vagus nerve stimulation, optogenetics, multiomics sequencing, and cytokine-targeted therapies. By integrating multidisciplinary perspectives, this review consolidates a theoretical framework for neuro-immune research and provides insights into precision medicine for related diseases. On the basis of synthesizing existing knowledge, it proposes promising research directions, identifies priorities and potential challenges for future investigations, and emphasizes the value of neuro-immune mechanisms in guiding therapeutic development—including target identification, design of individualized treatment strategies, and cross-disciplinary collaborative innovation to advance clinical interventions for neuro-immune diseases. Finally, the review delves into the recent advances and challenges in combined neuromodulation-immunotherapy strategies.
{"title":"Neuro-Immune Crosstalk: Molecular Mechanisms, Biological Functions, Diseases, and Therapeutic Targets","authors":"Xin Guo, Hui Liu, Yu-Jing Song, Jian-Hua Wang, Danfeng Liu, Zhi-Wei Zheng, Jia-Jun Li, Boya Li, An Song, Wei He, Lei-Lei Yang, Shuo Wang","doi":"10.1002/mco2.70497","DOIUrl":"10.1002/mco2.70497","url":null,"abstract":"<p>The advent of neuroimmunology has dismantled the traditional doctrine of the brain's immune privilege, uncovering a sophisticated and dynamic bidirectional regulatory interplay between the nervous and immune systems. This review synthesizes pivotal advances in neuroimmunology, integrating recent anatomical and molecular discoveries to refine the understanding of neuro-immune communication. It highlights the pathological roles of neurotransmitters, cytokines, and their signaling networks in neurodegenerative, psychiatric, and neoplastic diseases, while critically examining contested regulatory mechanisms. The review further evaluates the clinical translational potential and challenges of innovative strategies such as vagus nerve stimulation, optogenetics, multiomics sequencing, and cytokine-targeted therapies. By integrating multidisciplinary perspectives, this review consolidates a theoretical framework for neuro-immune research and provides insights into precision medicine for related diseases. On the basis of synthesizing existing knowledge, it proposes promising research directions, identifies priorities and potential challenges for future investigations, and emphasizes the value of neuro-immune mechanisms in guiding therapeutic development—including target identification, design of individualized treatment strategies, and cross-disciplinary collaborative innovation to advance clinical interventions for neuro-immune diseases. Finally, the review delves into the recent advances and challenges in combined neuromodulation-immunotherapy strategies.</p>","PeriodicalId":94133,"journal":{"name":"MedComm","volume":"7 2","pages":""},"PeriodicalIF":10.7,"publicationDate":"2026-01-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12828075/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146055584","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
The integration of artificial intelligence (AI) into surgical practices is advancing towards greater intelligence and precision. This study assesses the potential of AI in video-assisted thoracoscopic surgery (VATS) lobectomy for lung cancer by developing an AI system named LungSurg. LungSurg comprises two interconnected networks: a segmentation network for identifying intrathoracic anatomy and surgical instruments, and a classification network for recognizing surgical phases. We prospectively collected 222 VATS lobectomy videos from eight centers, generating over 32,000 annotations and more than one million frames with phase information. In external validation, the segmentation network achieved mean Average precision scores of 0.745 for the left lung and 0.726 for the right lung across various instruments and anatomical structures. The classification network demonstrated Top-1 and Top-3 accuracies of 71.5% and 88.0%, respectively, in identifying 14 surgical phases. Comparative experiments revealed that LungSurg performed comparably to senior surgeons in anatomical identification and surpassed them in sensitivity. In addition, an educational study showed that surgical residents trained with LungSurg significantly improved their anatomical identification and phase classification skills compared to those using conventional methods. These results indicate that LungSurg accurately analyzes VATS lobectomy procedures, highlighting the feasibility and potential of AI-driven tools in enhancing thoracic surgical practices.
{"title":"LungSurg: A Generative AI System for Segmentation and Phase Classification in Thoracoscopic Lobectomy","authors":"Hengrui Liang, Zeping Yan, Yudong Zhang, Keyao Dai, Hongyan Li, Jianfei Shen, Pengfei Li, Jipeng Jiang, Guochao Zhang, Xiang Zhang, Hao Chen, Honglang Zhang, Yuzhuo Zhang, Shujun Liang, Minsheng Chen, Xin Wang, Anyi Rao, Wei Wang, Lei Zhao, Yuchen Guo, Jianxing He","doi":"10.1002/mco2.70613","DOIUrl":"10.1002/mco2.70613","url":null,"abstract":"<p>The integration of artificial intelligence (AI) into surgical practices is advancing towards greater intelligence and precision. This study assesses the potential of AI in video-assisted thoracoscopic surgery (VATS) lobectomy for lung cancer by developing an AI system named LungSurg. LungSurg comprises two interconnected networks: a segmentation network for identifying intrathoracic anatomy and surgical instruments, and a classification network for recognizing surgical phases. We prospectively collected 222 VATS lobectomy videos from eight centers, generating over 32,000 annotations and more than one million frames with phase information. In external validation, the segmentation network achieved mean Average precision scores of 0.745 for the left lung and 0.726 for the right lung across various instruments and anatomical structures. The classification network demonstrated Top-1 and Top-3 accuracies of 71.5% and 88.0%, respectively, in identifying 14 surgical phases. Comparative experiments revealed that LungSurg performed comparably to senior surgeons in anatomical identification and surpassed them in sensitivity. In addition, an educational study showed that surgical residents trained with LungSurg significantly improved their anatomical identification and phase classification skills compared to those using conventional methods. These results indicate that LungSurg accurately analyzes VATS lobectomy procedures, highlighting the feasibility and potential of AI-driven tools in enhancing thoracic surgical practices.</p>","PeriodicalId":94133,"journal":{"name":"MedComm","volume":"7 2","pages":""},"PeriodicalIF":10.7,"publicationDate":"2026-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12820416/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146032566","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Anqi Lin, Minying Xiong, Aimin Jiang, Li Chen, Lihaoyun Huang, Kailai Li, Hank Z. H. Wong, Jian Zhang, Zaoqu Liu, Quan Cheng, Bufu Tang, Pengpeng Zhang, Peng Luo
Cancer immunotherapy has emerged as a transformative therapeutic strategy that harnesses the immune system to combat malignant tumors, overcoming critical limitations such as the nonspecific cytotoxicity of conventional chemotherapy and radiotherapy and drug resistance arising from target mutations in targeted therapies. Growing evidence demonstrates that the human microbiome plays a pivotal role in modulating immune responses and influencing the efficacy of immunotherapeutic interventions. Although the impact is increasingly recognized, the molecular mechanisms and translational potential of microbiome-based strategies remain incompletely explored. This review systematically elucidates how microorganisms from distinct anatomical sites (including bacteria, fungi, and viruses residing in the gut, oral cavity, skin, respiratory tract, and urogenital tract) and intratumoral microbes modulate the tumor immune microenvironment through metabolites, immune cell priming, and antigen mimicry. Furthermore, we discuss how specific microbial signatures predict responses to immune checkpoint inhibitors (ICIs) and CAR-T cell therapy, and highlight emerging interventional strategies, including fecal microbiome transplantation (FMT), probiotics, and engineered bacteria, that demonstrate synergistic effects with immunotherapy in preclinical and clinical settings. By integrating mechanistic insights with translational advances, this review provides a comprehensive scientific foundation for microbiome-based precision immunotherapy, aimed at improving patient survival outcomes and reducing treatment-related adverse events.
{"title":"Tumor Immunotherapy and Microbiome: From Bench-to-Bedside Applications","authors":"Anqi Lin, Minying Xiong, Aimin Jiang, Li Chen, Lihaoyun Huang, Kailai Li, Hank Z. H. Wong, Jian Zhang, Zaoqu Liu, Quan Cheng, Bufu Tang, Pengpeng Zhang, Peng Luo","doi":"10.1002/mco2.70454","DOIUrl":"10.1002/mco2.70454","url":null,"abstract":"<p>Cancer immunotherapy has emerged as a transformative therapeutic strategy that harnesses the immune system to combat malignant tumors, overcoming critical limitations such as the nonspecific cytotoxicity of conventional chemotherapy and radiotherapy and drug resistance arising from target mutations in targeted therapies. Growing evidence demonstrates that the human microbiome plays a pivotal role in modulating immune responses and influencing the efficacy of immunotherapeutic interventions. Although the impact is increasingly recognized, the molecular mechanisms and translational potential of microbiome-based strategies remain incompletely explored. This review systematically elucidates how microorganisms from distinct anatomical sites (including bacteria, fungi, and viruses residing in the gut, oral cavity, skin, respiratory tract, and urogenital tract) and intratumoral microbes modulate the tumor immune microenvironment through metabolites, immune cell priming, and antigen mimicry. Furthermore, we discuss how specific microbial signatures predict responses to immune checkpoint inhibitors (ICIs) and CAR-T cell therapy, and highlight emerging interventional strategies, including fecal microbiome transplantation (FMT), probiotics, and engineered bacteria, that demonstrate synergistic effects with immunotherapy in preclinical and clinical settings. By integrating mechanistic insights with translational advances, this review provides a comprehensive scientific foundation for microbiome-based precision immunotherapy, aimed at improving patient survival outcomes and reducing treatment-related adverse events.</p>","PeriodicalId":94133,"journal":{"name":"MedComm","volume":"7 2","pages":""},"PeriodicalIF":10.7,"publicationDate":"2026-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12820422/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146032484","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Adrián Hernández-Cacho, Jiaqi Ni, Jesús F. García-Gavilán, Prokopis Konstanti, Clara Belzer, Jesús Vioque, Dolores Corella, Montserrat Fitó, Josep Vidal, Laura Torres-Collado, Oscar Coltell, Nancy Babio, Javier Hernando-Redondo, Isabel Moreno-Indias, Miguel Ruiz-Canela, Francisco J. Tinahones, Jordi Salas-Salvadó
The interplay between diet, gut microbiota, and depressive symptoms is increasingly recognized, but underlying mechanisms remain unclear. We investigated whether adherence to several dietary patterns relates to gut microbial signatures and whether these profiles are associated with depressive symptoms in an elderly Mediterranean cohort. In 644 participants, 16S ribosomal RNA gene sequencing and dietary intake from a food-frequency questionnaire were obtained at baseline and 1-year follow-up. Adherence scores were computed for the Mediterranean diet adherence score (MEDAS), energy-reduced MEDAS (erMEDAS), Dietary Approaches to Stop Hypertension (DASH), Healthy Plant-Based Diet Index (HPDI), Unhealthy Plant-Based Diet Index (UPDI), and Western Diet Score (WESTDIET). Healthy patterns (erMEDAS, MEDAS, DASH, HPDI) were associated with 22, 28, 24, and 16 genera, of which 82%, 75%, 79%, and 88% showed a protective profile (more abundant with lower, or less abundant with higher, depressive symptoms). UPDI and WESTDIET were associated with 20 and 27 genera, but only 25% and 26% were protective. Mediation analyses indicated that gut microbiota mediated the associations of MEDAS (ACME = –0.066, p = 0.006) and erMEDAS (ACME = –0.029, p = 0.011) with depressive symptoms. This study is among the first to test whether diet shapes a microbiota signature that mediates the diet–depression relationship, adding mechanistic insight into diet–mental health research.
饮食、肠道菌群和抑郁症状之间的相互作用越来越被认识到,但潜在的机制仍不清楚。我们调查了在地中海老年队列中坚持几种饮食模式是否与肠道微生物特征有关,以及这些特征是否与抑郁症状有关。在644名参与者中,在基线和1年随访期间,通过食物频率问卷获得16S核糖体RNA基因测序和饮食摄入量。计算地中海饮食依从性评分(MEDAS)、能量降低的MEDAS (erMEDAS)、停止高血压的饮食方法(DASH)、健康植物性饮食指数(HPDI)、不健康植物性饮食指数(UPDI)和西方饮食评分(WESTDIET)的依从性评分。健康模式(erMEDAS、MEDAS、DASH、HPDI)与22、28、24和16个属相关,其中82%、75%、79%和88%显示出保护性特征(抑郁症状越丰富,抑郁症状越低,抑郁症状越少)。UPDI和WESTDIET分别与20和27个属相关,但只有25%和26%具有保护作用。中介分析表明,肠道微生物群介导了MEDAS (ACME = -0.066, p = 0.006)和erMEDAS (ACME = -0.029, p = 0.011)与抑郁症状的关联。这项研究首次测试了饮食是否会影响微生物群特征,从而调节饮食与抑郁的关系,为饮食与心理健康的研究增加了机制上的见解。
{"title":"The Gut Microbiota as a Mediator in the Relationship Between Dietary Patterns and Depression","authors":"Adrián Hernández-Cacho, Jiaqi Ni, Jesús F. García-Gavilán, Prokopis Konstanti, Clara Belzer, Jesús Vioque, Dolores Corella, Montserrat Fitó, Josep Vidal, Laura Torres-Collado, Oscar Coltell, Nancy Babio, Javier Hernando-Redondo, Isabel Moreno-Indias, Miguel Ruiz-Canela, Francisco J. Tinahones, Jordi Salas-Salvadó","doi":"10.1002/mco2.70562","DOIUrl":"10.1002/mco2.70562","url":null,"abstract":"<p>The interplay between diet, gut microbiota, and depressive symptoms is increasingly recognized, but underlying mechanisms remain unclear. We investigated whether adherence to several dietary patterns relates to gut microbial signatures and whether these profiles are associated with depressive symptoms in an elderly Mediterranean cohort. In 644 participants, 16S ribosomal RNA gene sequencing and dietary intake from a food-frequency questionnaire were obtained at baseline and 1-year follow-up. Adherence scores were computed for the Mediterranean diet adherence score (MEDAS), energy-reduced MEDAS (erMEDAS), Dietary Approaches to Stop Hypertension (DASH), Healthy Plant-Based Diet Index (HPDI), Unhealthy Plant-Based Diet Index (UPDI), and Western Diet Score (WESTDIET). Healthy patterns (erMEDAS, MEDAS, DASH, HPDI) were associated with 22, 28, 24, and 16 genera, of which 82%, 75%, 79%, and 88% showed a protective profile (more abundant with lower, or less abundant with higher, depressive symptoms). UPDI and WESTDIET were associated with 20 and 27 genera, but only 25% and 26% were protective. Mediation analyses indicated that gut microbiota mediated the associations of MEDAS (ACME = –0.066, <i>p</i> = 0.006) and erMEDAS (ACME = –0.029, <i>p</i> = 0.011) with depressive symptoms. This study is among the first to test whether diet shapes a microbiota signature that mediates the diet–depression relationship, adding mechanistic insight into diet–mental health research.</p>","PeriodicalId":94133,"journal":{"name":"MedComm","volume":"7 2","pages":""},"PeriodicalIF":10.7,"publicationDate":"2026-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12820420/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146032569","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}